on March 27, 2003
Published online before print March 27, 2003, doi: 10.1161/01.ATV.0000069210.46539.0D
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on October 2, 2002
Accepted on March 13, 2003
Troglitazone Stimulates Repair of the Endothelium and Inhibits Neointimal Formation in Denuded Rat Aorta
Katherine M. Hannan ;
From the Cell Biology of Diabetes Laboratory (K.M.H., S.T.d.D., P.J.L.) and Morphology Laboratory (R.J.D.), Baker Heart Research Institute, Melbourne 8008, Victoria, Australia.
* To whom correspondence should be addressed. E-mail: peter.little{at}baker.edu.au.
Objective--Vascular endothelium is emerging as a therapeutic target for atherosclerotic macrovascular disease in diabetes using oral hypoglycemic agents with pleiotropic actions. We have addressed whether the thiazolidinedione troglitazone has effects on the endothelial cell response to injury in rat aorta and its interaction with the growth response of underlying vascular smooth muscle.
Methods and Results--Repair of rat aorta after balloon catheter injury in troglitazone-treated (400 mg/kg per day by mouth) rats showed early acceleration of reendothelialization and late reduction in neointima formation. Complementary in vitro studies showed that troglitazone dose-dependently inhibited migration and proliferation of cultured macrovascular endothelial and vascular smooth muscle cells in low-glucose (5 mmol/L) and high-glucose (25 mmol/L) media. However, in endothelial cells, the inhibitory response at low (<3 µmol/L) troglitazone concentrations resulted from direct inhibition of proliferation, whereas inhibition at higher (10 µmol/L) concentrations was secondary to apoptosis and necrosis. Additional studies indicated a concentration-specific activity of troglitazone to protect endothelial cells from apoptosis.
Conclusions--Troglitazone had effects consistent with maintenance of vascular integrity and protection against mechanisms of atherosclerosis and restenosis, which may arise from a concentration-specific effect to reduce high rates of apoptosis occurring in cultured cells and repairing vessels.
Key words: troglitazone • endothelial cells • vascular smooth muscle cells • reendothelialization • apoptosis • proliferation • migration
This article has been cited by other articles:
 |
|
 |
|
  A. V. Finn, M. John, G. Nakazawa, R. Polavarapu, V. Karmali, X. Xu, Q. Cheng, T. Davis, C. Raghunathan, E. Acampado, et al. Differential Healing After Sirolimus, Paclitaxel, and Bare Metal Stent Placement in Combination With Peroxisome Proliferator-Activator Receptor {gamma} Agonists: Requirement for mTOR/Akt2 in PPAR{gamma} Activation Circ. Res., November 6, 2009; 105(10): 1003 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Weber, A. Schober, and A. Zernecke Chemokines: Key Regulators of Mononuclear Cell Recruitment in Atherosclerotic Vascular Disease Arterioscler Thromb Vasc Biol, November 1, 2004; 24(11): 1997 - 2008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Marx, H. Duez, J.-C. Fruchart, and B. Staels Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells Circ. Res., May 14, 2004; 94(9): 1168 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-H. Wang, N. Ciliberti, S.-H. Li, P. E. Szmitko, R. D. Weisel, P. W.M. Fedak, M. Al-Omran, W.-J. Cherng, R.-K. Li, W. L. Stanford, et al. Rosiglitazone Facilitates Angiogenic Progenitor Cell Differentiation Toward Endothelial Lineage: A New Paradigm in Glitazone Pleiotropy Circulation, March 23, 2004; 109(11): 1392 - 1400. [Abstract] [Full Text] [PDF]
|
|